CLINICAL_TRIALS
trial_result
· 2020-09-01
Clinical Trial Update: Study of Rapastinel as Monotherapy in Patients With MDD [Phase 3]
Summary
Phase 3 trial of rapastinel as monotherapy for major depressive disorder was terminated; results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Naurex, Inc, an affiliate of Allergan plc | Conditions: Depressive Disorder, Major | Phase 3 | Status: TERMINATED | Results posted: 2020-09-01